Asset Details
Do you wish to reserve the book?
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients
Do you wish to request the book?
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients
2014
Overview
Background
Repeated exposure to peritoneal dialysis (PD) solutions contributes to cumulative intraperitoneal inflammation and peritoneal injury. The present study aimed to explore the capacity of dialysate interleukin-6(IL-6) to a) predict peritoneal membrane function and peritonitis in incident PD patients, and b) to evaluate the influence of neutral pH, low glucose degradation product (GDP) PD solution on dialysate IL-6 levels.
Methods
The study included 88 incident participants from the balANZ trial who had completed 24-months of follow-up. Change in peritoneal solute transport rate (PSTR) and peritonitis were primary outcome measures, and the utility of IL-6 and IL-6 appearance rate (IL-6 AR) in predicting these outcomes was analyzed using multilevel linear regression and Cox proportional hazards models, respectively. Sensitivity analyses were performed by analyzing outcomes in a peritonitis-free cohort (n = 56).
Results
Dialysate IL-6 concentration significantly increased from baseline to 24 months (mean difference 19.07 pg/mL;
P
< 0.001) but was not affected by the type of PD solution received (
P
= 0.68). An increase in PSTR from baseline was associated with higher levels of IL-6 (
P
= 0.004), the use of standard solutions (
P
= 0.005) and longer PD duration (
P
< 0.001). Baseline IL-6 level was not associated with a shorter time to first peritonitis (adjusted hazard ratio 1.00, 95% CI 0.99-1.00,
P
= 0.74). Analysis of IL-6 AR as well as sensitivity analyses in a peritonitis-free cohort yielded comparable results.
Conclusion
Dialysate IL-6 concentration increased with longer PD duration and was a significant, independent predictor of PSTR. The use of biocompatible PD solutions exerted no significant effect on dialysate IL-6 levels but did abrogate the increase in PSTR associated with standard PD solutions. This is the first study to examine the impact of biocompatible solutions on the utility of IL-6 in predicting PSTR and peritonitis.
Publisher
BioMed Central,BioMed Central Ltd,Springer Nature B.V
